drug
ensartinib hydrochloride
Marketedupdated 3mo agoby Xcovery Holdings Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3indications
investigational
NSCLC
all catalysts(3)
Trials studying ensartinib hydrochloride
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 9, 2029
~2.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Jun 1, 2037compositionUS 10899744
- Jun 1, 2037compositionUS 10899744
- Nov 29, 2031compositionUS 9126947
- Nov 29, 2031compositionUS 9126947
- Jun 18, 2029compositionUS 92967242.8y
- Jun 18, 2029compositionUS 92967242.8y
- Feb 9, 2029compositionUS 85519952.5y
- Feb 9, 2029compositionUS 85519952.5y
FDA exclusivities (2)
- Dec 18, 2029NCENew Chemical Entity (5y)3.3y
- Dec 18, 2029NCENew Chemical Entity (5y)3.3y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that